Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
The oral activin A receptor type I, Janus kinase 1 (JAK1), and JAK2 inhibitor momelotinib demonstrated symptom, spleen, and anemia benefits in intermediate- and high-risk myelofibrosis (MF). Post hoc analyses herein evaluated the efficacy and safety of momelotinib in patients with MF and thrombocyto...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Wiley
2023-11-01
|
| 叢編: | HemaSphere |
| 在線閱讀: | http://journals.lww.com/10.1097/HS9.0000000000000963 |